AddedRisk Factors
For additional information regarding risk associated with legal proceedings other than those related to intellectual property, See “Our business and operations could be negatively affected by any pending or future securities litigation.”
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Competition in our industry for highly skilled scientific, healthcare and sales personnel is intense and we may compete with larger pharmaceutical companies that likely will have access to greater financial resources than we do. As we expand our product
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Changes to management or other key personnel, including the recent turnover in our leadership and senior management team, could have an adverse effect on our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Our success is substantially dependent upon the performance, contributions and expertise of our executive leadership, senior management team and other key personnel. Our executive leadership, senior management team and other key personnel play a significant role in formulating and executing on our long-term strategy, generating business and overseeing operations. We have experienced, and may continue to experience, significant executive management changes, including the consolidation of roles and responsibilities. Brian Markison, our former Chief Executive Officer (“CEO”), retired from the Company effective December 31, 2025, and Mary Anne Heino, the Chair of our Board of Directors, is serving as our CEO as of January 1, 2026 while the Board of Directors conducts a comprehensive search for our next CEO. Our former President, Paul Blanchfield, accepted a role with another company and left the Company in November 2025. We also have experienced and may continue to experience the departure and transition of other members of the leadership team.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
Obtaining adequate coding, coverage, and payment for PYLARIFY is critical, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels to adequately cover our customers’ costs of using PYLARIFY in PET/computed tomography (“CT”) imaging procedures. The Healthcare Procedure Coding System code for PYLARIFY, which enables streamlined billing, went into effect as of January 1, 2022. In addition, effective January 1, 2022, the Centers for Medicare and Medicaid Services (“CMS”) granted TPT Status for PYLARIFY, enabling traditional Medicare
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
A critical ingredient of TechneLite is Mo-99. We currently purchase finished Mo-99 from three of the four main processing sites in the world, namely Institute for Radioelements (“IRE”) in Belgium, NTP Radioisotopes (“NTP”) in South Africa and Australian Nuclear Science and Technology Organisation (“ANSTO”) in Australia. These processing sites provide us Mo-99 from five of the six main Mo-99-producing reactors in the world, namely BR2 in Belgium, LVR-15 in the Czech Republic, HFR in The Netherlands, SAFARI in South Africa and OPAL in Australia.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Although we have a globally diverse Mo-99 supply with IRE in Belgium, NTP in South Africa, and ANSTO in Australia, we still face supplier and logistical challenges in our Mo-99 supply chain. When one supplier experiences outages, we generally rely on Mo-99 supply from the other suppliers to limit the impact of the outages. We believe we effectively manage these various supply chain challenges, but depending on reactor and processor schedules and operations, at times we have not been able to fill some or all of the demand for our TechneLite generators on certain manufacturing days. A prolonged disruption of service from one of our three Mo-99 processing sites or one of their main Mo-99-producing reactors could have a substantial negative effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
U.S., Canadian and international governments have encouraged the development of a number of alternative Mo-99 production projects with existing reactors and technologies as well as new technologies. However, we cannot say when, or if, the Mo-99 produced from these projects will become available. As a result, there is a limited amount of Mo-99 available which could limit the quantity of TechneLite that we could manufacture, sell and distribute, resulting in a substantial negative effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Most of the global suppliers of Mo-99 rely on Framatone-CERCA in France to fabricate uranium targets and in some cases fuel for research reactors from which Mo-99 is produced. Absent a new supplier, a supply disruption relating to uranium targets or fuel could have a substantial negative effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
DEFINITY is an ultrasound enhancing agent based on perflutren lipid microspheres. In 2007, the FDA received reports of deaths and serious cardiopulmonary reactions following the administration of ultrasound enhancing agents used in echocardiography. Four of the 11 reported deaths were caused by cardiac arrest occurring either during or within 30 minutes following the administration of the ultrasound enhancing agent; most of the serious but non-fatal reactions also occurred in this time frame. As a result, in October 2007,
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
The full impact on our business of healthcare reforms and other new laws, or changes in existing laws, is uncertain. Nor is it clear whether additional legislative changes will be adopted or how those changes would affect our industry in general or our ability to successfully commercialize our products or develop or commercialize new products. It is also unclear exactly how the results of the 2024 election will impact healthcare reform measures of the previous administration or whether the new administration could impose other reform efforts, including what, if any, impact this will have on our business.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Similarly, in June of 2024, Endocyte, Inc. (“Endocyte”), Novartis and Purdue Research Foundation sued POINT Biopharma Global Inc. (“POINT”) and Lilly alleging that POINT’s manufacturing and sale of PNT2002 infringes an Endocyte patent that discloses PSMA-binding conjugates useful for delivery targeted therapeutic, diagnostic and imaging agents, including radiopharmaceuticals. While we have not been named as a party to the lawsuit, if POINT is found to be infringing on proprietary rights of Endocyte, it could prevent or result in a delay in our development and commercialization of PNT2002 or otherwise have an adverse effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
If we lose the services of our key personnel, our business could be adversely affected.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
The healthcare industry is characterized by continuous technological development resulting in changing customer preferences and requirements. The success of new product development depends on many factors, including our ability to fund development of new products or new indications for existing products, anticipate and satisfy customer needs, obtain timely regulatory approval based on performance of our products in development versus their clinical trial comparators, develop and manufacture products in a cost-effective and timely manner, maintain advantageous positions with respect to intellectual property and differentiate our products from our competitors. To compete successfully in the marketplace, we must make substantial investments in new product development, whether internally or externally through licensing or acquisitions. Our failure to introduce new and innovative products in a timely manner would have an adverse effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Even if we are able to develop, manufacture and obtain regulatory approvals for our new products, the success of these products would depend upon market acceptance and adequate coding, coverage and payment. Levels of market acceptance for our new products could be affected by a number of factors, including:
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
•The breadth of indications in which alternative products from our competitors can be marketed;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedRisk Factors
Although PYLARIFY is broadly available across the U.S., we We also continue to seek qualification for additional PMFs in 2025 2026 and we can give no assurance that additional PMF sites will have the capacity to produce Neuraceq in addition to other products they may already produce, including other F-18-based products, that those PMF sites will be willing to commit to manufacture Neuraceq and successfully complete the technology transfer process necessary to manufacture Neuraceq, that the FDA will continue to approve PMFs in accordance with our expansion plans to meet increasing product demand or that PYLARIFY Neuraceq will always be available at the specific time of day preferred by the end-users. end-users or that our expansion plans accurately predict demand growth.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although PYLARIFY is broadly available across the U.S., United States, we will continue to seek qualification for additional PMFs in 2025 2026 and can give no assurance that additional PMF sites will have the capacity to produce PYLARIFY in addition to other products they may already produce, including other F-18-based products, that those PMF sites will be willing to commit to manufacture PYLARIFY and successfully complete the technology transfer process necessary to manufacture PYLARIFY, that the FDA will continue to approve PMFs in accordance with our expansion plans to meet increasing demand or product demand, that PYLARIFY will always be available at the specific time of day preferred by the end-users. end-users or that our expansion plans accurately predict demand growth.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We cannot anticipate the actions of our current or future competitors in the same or competing modalities, such as significant price reductions on products that are competitive with our own, the ability to offer a portfolio of products and offer price reductions across a portfolio, development of new products that are more cost-effective or have superior performance or higher reimbursement than our current products or products, potential future products or the introduction of generic versions of our proprietary products. products, the ability to secure better manufacturing locations or times for production of current or future products that limit the availability of necessary raw materials, production equipment, components or radiopharmacist time or, for our diagnostic agents, PET scanner capacity.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We may be limited in our ability to use these tax loss carryforwards to reduce our future U.S. federal and state income tax liabilities if our future income is not sufficient to absorb the losses, or if we were to experience another “ownership change” as specified in Section 382 of the Internal Revenue Code including if we were to issue a certain amount of equity securities, certain of our stockholders were to sell shares of our common stock, or we were to enter into certain strategic transactions. losses.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we have qualified and continue to qualify additional PMFs, we can give no assurance that additional PMF sites will have the capacity to produce PYLARIFY and Neuraceq in addition to other products they may already produce, including other F-18-based products, that those PMF sites will be willing to commit to manufacture PYLARIFY and Neuraceq and successfully complete the technology transfer process necessary to manufacture PYLARIFY and Neuraceq, that the FDA will continue to approve PMFs in accordance with our planned roll-out schedule or that the PMFs will not experience issues with their ability to manufacture and deliver PYLARIFY or Neuraceq to our customers.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In 2024, October 2025, we held a pre-NDA meeting with announced that the FDA and we expect to submit a new drug application (“NDA”) had accepted our NDA for MK-6240 in 2025, and has set a PDUFA target action date of August 13, 2026, but we can provide no assurance that we will meet that expected timeline, that our NDA will be accepted by the FDA, that MK-6240 will be approved by the FDA based on the data submitted or, if approved, that we will be successful in commercializing MK-6240.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In November 2024, July 2025, our Board of Directors (the “Board”) authorized a program to repurchase up to $250.0 $400.0 million over the next twelve months of shares of our common stock through December 31, 2027, via open market purchases or purchases, privately negotiated transactions, block trades and/or or pursuant to trades intending to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations (the “2024 “2025 Program”).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
As described further under Part I, Item 1., “Business - Regulatory Matters-Hatch Waxman Act,” of this is the date after which Form 10-K, the FDA is allowed to accept an Abbreviated New Drug Application (“ANDA”) or 505(b)(2) applications application one year prior to the NCE expiration date under certain circumstances, specifically, from a generic challenger that include includes a Paragraph IV certification, from generic challengers. “Paragraph IV” Certification against each of the six patents we have listed in the Orange Book.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If production capacity is not available, FDA approval of manufacturing sites is delayed or withdrawn or if withdrawn, FDA requirements relating to site approval change, change in a way that impacts our ability to meet demand for Neuraceq or end users scheduling needs or if we invest to extend our PMF network and demand does not grow to meet the expanded capacity, our business, results of operations, financial condition and cash flows could would be adversely affected.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our Accordingly, our ability to continue to generate substantial revenue from PYLARIFY, grow PYLARIFY Neuraceq, and to successfully launch new PET diagnostic products, including MK-6240 the new formulation of our PSMA PET imaging agent, MK-6240, LNTH-2501 and NAV-4694, is dependent upon the availability of such staff at imaging centers and hospitals and PET scanners generally. generally and our ability to ensure on time availability of our products to meet user needs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our ability to continue to grow Continued substantial revenue contribution from PYLARIFY as a commercial product is dependent on (A) the ability of positron emission tomography (“PET”) manufacturing facilities (“PMFs”) to manufacture PYLARIFY to meet product demand or demand, including ensuring that PYLARIFY will always be is available at the specific time of day preferred by the end-user, (B) our ability to maintain ensure adequate coding, coverage and payment for PYLARIFY, (C) our ability to promote PYLARIFY to customers and to maintain PYLARIFY as the most a widely utilized prostate-specific membrane antigen (“PSMA”) PET imaging agent, including after which has been impacted by the expiration of transitional pass-through payment status (“TPT Status”) at the end of on December 31, 2024, (D) whether and when a potential generic version of PYLARIFY may enter the market and (E) our ability to clinically and commercially differentiate PYLARIFY from other competitive products.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Continued growth and Substantial revenue contribution from PYLARIFY will also depend on our ability to clinically differentiate PYLARIFY in light from competitive products so that customers continue to choose PSMA PET with PYLARIFY for appropriate patients because of its clinical differentiation and despite the loss of TPT Status, including through flexible and dependable access to PYLARIFY nationally, a best-in-class customer experience and through long-term strategic contracts. continued promotion and education regarding PYLARIFY’s clinical and commercial attributes.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
While we have experienced some turnover on our executive leadership team, we have generally been able to fill positions by either promoting existing employees or attracting new, qualified individuals to lead key functional areas.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
To obtain regulatory approval for these products, we must may need to conduct extensive human tests, which are referred to as clinical trials, as well as meet other rigorous regulatory requirements, as further described in Part I, Item 1.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If However, if such a right becomes available again and if one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by arranging for one or more financial institutions to take the Notes from converting holders and pay such holders in accordance with the Indenture, we would be required to settle any converted principal amount of such Notes through the payment of cash and by paying or delivering, at our election, cash, shares of our common stock, or a combination of cash and shares, with respect to the remainder of our conversion obligation in excess of the aggregate principal amount of the Notes being converted, which could adversely affect our liquidity or, if we elect to settle our conversion obligation in excess of the aggregate principal amount of the Notes being converted in shares of common stock (whether in whole or in part), could dilute the ownership interests of our existing common stockholders.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our stock price could fluctuate has fluctuated significantly, which could cause the value of your investment in our common stock to decline, and you may not be able to resell your shares at or above your purchase price.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We are headquartered in Massachusetts, with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On January 1, 2026, we completed the sale of our single-photon emission computerized tomography (“SPECT”) business to SHINE Technologies, LLC (“SHINE”), a wholly-owned subsidiary of Illuminated Holdings, Inc. We are entitled to receive total consideration of up to $155.0 million, consisting of cash, a convertible installment note, a term note and contingent earnout payments. Under the terms of the definitive agreement, SHINE acquired the assets and liabilities associated with our SPECT business, including its approved products (TechneLite, NEUROLITE, Xenon Xe-133 Gas, and Cardiolite), the portion of the North Billerica, Massachusetts campus that manufactured our SPECT products and the SPECT-related Canadian operations. The transaction allows us to focus on growing our commercial portfolio of innovative PET radiodiagnostics and microbubbles, while advancing our pipeline of radiopharmaceuticals.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Effective November 7, 2025, Mary Anne Heino, the Chair of our Board of Directors (the “Board”), was appointed to serve as our Executive Chair and principal executive officer. Additionally, on January 1, 2026 (the “Effective Date”), Ms. Heino became our Chief Executive Officer (“CEO”), following the retirement of our former CEO, Brian Markison on December 31, 2025. Ms. Heino will serve as CEO until such time as the Board completes the comprehensive search process that it initiated to
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
identify and appoint the Company’s next CEO. Mr. Markison has agreed to serve as a strategic advisor to the Company through at least March 31, 2026.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In October 2025, we announced that the FDA has set a PDUFA target action date of March 29, 2026 for LNTH-2501. LNTH-2501 is a diagnostic kit for the preparation of Gallium-68 (“Ga-68”) edotreotide injection, which has been studied for use with PET imaging for localization of somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In October 2025, we announced that the FDA had accepted our New Drug Application (“NDA”) for MK-6240, our registrational F-18 tau-targeted PET imaging agent for the detection of tau neurofibrillary tangle pathology in patients with cognitive impairment being evaluated for Alzheimer’s disease, and has set a PDUFA target action date of August 13, 2026. During the second quarter of 2025, we announced that MK-6240 successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. The data from these two studies supported our NDA submission to the FDA. MK-6240 previously received Fast Track designation from the FDA for its potential to address an unmet medical need in Alzheimer’s disease diagnostics.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On September 24, 2025, we announced an exclusive licensing agreement for GE HealthCare Limited (“GE Healthcare”) to develop, manufacture, and commercialize Lantheus’ piflufolastat F-18 PET imaging agent (marketed in the United States as PYLARIFY) in Japan for prostate cancer diagnostics and companion diagnostic use. Under the terms of the agreement, GE Healthcare paid us an upfront license fee and will pay us development milestones and tiered royalties based on product sales in Japan.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In August 2025, we announced that the FDA had accepted our NDA for a new formulation of our F-18 PSMA PET imaging agent, filed by our subsidiary Aphelion, and that the FDA has set a PDUFA target action date of March 6, 2026. The new formulation was designed to enhance product stability and increase batch production, with the potential to enhance supply flexibility and improve operating leverage across the network. If the NDA is approved, we plan to work closely with clinicians and PMF sites to ensure a smooth rollout of the new formulation, including providing clear guidance on ordering, handling, and clinical use to support continuity of care for patients, and we plan to apply for reimbursement from the Centers for Medicare & Medicaid Services (“CMS”) for the new formulation, including seeking three years of TPT Status.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On July 21, 2025, we acquired Life Molecular, pursuant to the terms of the Sale and Purchase Agreement with Life Medical Group Limited (“Life Medical”) and Life Healthcare Group Holdings Limited (the “Sale and Purchase Agreement” and, such acquisition, the “LMI Acquisition”). Life Molecular, headquartered in Berlin, Germany, possesses an Alzheimer’s disease radiodiagnostic commercial infrastructure, research and development (“R&D”) capabilities, and an established international footprint. The LMI Acquisition includes Neuraceq, an Alzheimer’s disease radiodiagnostic. Neuraceq is commercially approved in the United States, Canada, the European Union, the United Kingdom, Switzerland, China, Japan, South Korea, and Taiwan.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
As consideration for the LMI Acquisition, we remitted an upfront payment of $355.2 million in cash, and could be required to pay up to an additional $400.0 million in potential earn-out and milestone payments. In November 2025 and in accordance with the terms of the Sale and Purchase Agreement, we finalized the net working capital accounts with Life Medical and we received a $2.3 million payment from Life Medical. This $2.3 million payment was recorded as an adjustment to purchase
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
consideration in the fourth quarter of 2025. Additionally, we assumed a contingent consideration liability owed to Piramal Holdings SA (“Piramal”), pursuant to a Securities Purchase Agreement between Piramal and Life Molecular.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In connection with the LMI Acquisition, the RM2 Sublicense Agreement was amended to (i) reduce the contingent regulatory and development milestones by €45.0 million; (ii) assign the right to future payments from Life Molecular to its former parent, Life Medical; and (iii) eliminate certain other non-substantive rights contained in the RM2 Sublicense Agreement (the “RM2 Amendment”). We determined that the RM2 Amendment did not constitute settlement of a pre-existing relationship in accordance with Accounting Standards Codification 805, “Business Combinations”, and concluded that the amendment represented a modification to the RM2 Sublicense Agreement, whereby we did not reacquire any incremental rights or assets. Accordingly, we will continue to account for the RM2 Sublicense Agreement as an asset acquisition, separate from the LMI Acquisition. We may be required to pay Life Medical additional milestone payments and royalties in connection with the RM2 Asset Purchase. GRPR is a member of the bombesin G protein-coupled receptor family, which has been found to be overexpressed in multiple cancers. First-in-human dosimetry showed a favorable safety and dosimetry profile and confirmed preclinical data demonstrating dose-dependent efficacy of LNTH-2402. We submitted investigational new drug applications in support of a Phase 1b/2 clinical trial with the LNTH-2401/LNTH-2402 theranostic pair in prostate cancer patients in the fourth quarter of 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
Our executive offices are located in Bedford, Massachusetts, with additional offices in North Billerica, Massachusetts; Montreal, Canada; and Lund, Sweden.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On January 13, 2025, we announced that we entered into a definitive agreement to acquire Life Molecular Imaging Ltd. (“Life Molecular”). Life Molecular is based in Berlin, Germany and is dedicated to advancing novel PET radiopharmaceutical diagnostics. The definitive agreement provides for an upfront payment of $350.0 million and up to an additional $400.0 million in potential earn-out and milestone payments. The transaction is expected to close in the second half of 2025, subject to the satisfaction of customary regulatory and closing conditions.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Pursuant to the Evergreen Merger Agreement, we will pay an upfront amount of $250 million, payable in cash at closing and subject to customary adjustments as set forth in the Evergreen Merger Agreement, and milestone payments in an aggregate additional cash amount of up to $752.5 million upon the occurrence of certain Milestone Trigger Events (as set forth in the Evergreen Merger Agreement). We also agreed to provide up to $18 million in unsecured loans to Evergreen on the terms set forth in the Merger Agreement. The Evergreen Merger is expected to close in the second half of 2025, subject to the satisfaction of customary regulatory and closing conditions.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On January 22, 2024, we purchased 56,342,355 shares of Perspective’s common stock (“Perspective Shares”) at a purchase price of $0.37 per share in a private placement transaction, for approximately $20.8 million in cash. We were also granted certain pro rata participation rights to maintain our ownership position in Perspective in the event that Perspective makes any public or non-public offering of any equity or voting securities, subject to certain exceptions.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On March 6, 2024, we purchased 60,431,039 Perspective Shares at a price of $0.95 per share. The total consideration for this additional purchase was approximately $57.4 million, resulting in Lantheus Alpha holding approximately 19.90% of the outstanding Perspective Shares (or 17.35% on a fully diluted basis) as of March 6, 2024.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On June 14, 2024, Perspective effected a 1-for-10 reverse stock split, after which we held 11,677,339 Perspective Shares.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On March 1, 2024, Brian Markison, our then Chair of our Board of Directors (the “Board”), became our Chief Executive Officer (“CEO”), and Mary Anne Heino, retired as our CEO and became the Chair of our Board. As part of this leadership transition, Mr. Markison assumed the role of Executive Chair of the Board as of January 23, 2024 until the effectiveness of his CEO appointment in March, and Board Member Julie McHugh became Lead Independent Director.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
As part of our evolution into a fully integrated radiopharmaceutical company, during 2024, we reviewed our current capabilities and skillsets and began implementing organizational changes deemed necessary to best position us to execute on our long-term strategy. These changes included transitioning approximately 60 employees out of the Company. In connection with these changes, we approved equity modifications that allowed grants of stock options and restricted stock units (“RSUs”) issued to those impacted by this event to continue to vest in 2024 and 2025 with any unvested stock option and RSU grants as of December 31, 2025 to be cancelled. Total stockholder return awards granted to these individuals will continue to vest on their original vesting schedule but any shares issued will be issued in a pro-rated amount based on the time served during the performance period.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
In September 2023, MK-6240 was granted Fast Track designation by the FDA. In February 2024, we announced the inclusion of MK-6240 in the National Institute on Aging-sponsored study called CLARiTI that enables the consortium to use MK-6240 in its investigation of Alzheimer’s disease and related dementias. The CLARiTI study will involve all 37 Alzheimer’s Disease Research Centers in the United States and will recruit 2,000 subjects and collect their imaging and blood-based biomarker data to generate etiologic profiles for cases of mixed dementia.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
In 2024, we held a pre-NDA meeting with the U.S. Food and Drug Administration (“FDA”) and we expect to submit an NDA for MK-6240 in 2025, but we can provide no assurance that we will meet that expected timeline, that our NDA will be accepted by the FDA, that MK-6240 will be approved by the FDA or, if approved, that we will be successful in commercialization.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On August 15, 2023, we announced that we would discontinue the production and promotion of AZEDRA and wind down our Somerset Facility. We continued manufacturing AZEDRA during the first quarter of 2024, to provide doses of AZEDRA to then-current patients so they could complete their treatment regimen. No AZEDRA was manufactured after March 1, 2024, when we transferred the assets and associated sublease of our Somerset Facility to Perspective.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Our Healthcare Procedure Coding System code, which enables streamlined billing, went into effect as of January 1, 2022. In addition, from January 1, 2022 to December 31, 2024, PYLARIFY had TPT Status from the Centers for Medicare and Medicaid Services (“CMS”) in the hospital outpatient setting, enabling traditional Medicare FFS to provide separate payment for PYLARIFY in addition to the payment for the PET/computed tomography (“CT”) procedure in that setting.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedMD&A
Net cash provided by operating activities of $544.8 $390.1 million during the year ended December 31, 2024 2025 was primarily comprised of net income adjusted for the net effect of non-cash items such as unrealized loss on investment in equity securities, charges incurred in connection with the Perspective IPR&D exclusive license options, charges related to Radiopharm’s licensed assets, charges related to Life Molecular’s RM2 license, gains on disposal adjustments to the fair value of our Somerset Facility asset retirement obligation and a portion of our North Billerica, Massachusetts facility, contingent assets and liabilities, depreciation, amortization and accretion expense expense, deferred taxes and stock-based compensation expense.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
(“Evergreen”) On April 1, 2025, we acquired all the issued and Shareholder Representative Services LLC, pursuant to which we will acquire outstanding shares of Evergreen by means of a statutory merger of our subsidiary with and into Evergreen, with Evergreen surviving as our wholly-owned subsidiary (the “Evergreen Merger”). Merger”), pursuant to the terms of the Agreement and Plan of Merger (the “Evergreen Merger Agreement”) with Evergreen and Shareholder Representative Services LLC.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our plan to successfully grow PYLARIFY our PSMA PET franchise includes obtaining approval for and commercializing a new formulation of our F-18 PSMA PET imaging agent, conveying its our product’s commercial and clinical value, negotiating and realizing the benefits from strategic contracts with customers in the United States, expanding its use PSMA PET in appropriate new patient populations, and through strategic partnerships and collaborations, including outside of the U.S. United States.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
(in thousands) Rebates and Allowances Balance, Balance at January 1, 2023 $ 13,399 Provision related to current period revenues 32,308 Adjustments relating to prior period revenues (453) 31,855 Payments or credits made during the period (29,184) Balance, Balance at December 31, 2023 16,070 Provision related to current period revenues 63,504 Payments or credits made during the period (54,326) Balance, Balance at December 31, 2024 25,248 Provision related to current period revenues 167,628 Payments or credits made during the period (126,428) Balance at December 31, 2025 $ 25,248 66,448
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Previously, on July 3, 2024,we acquired from Life Molecular the global rights to RM2, its clinical stage RM2, a stage, gastrin-releasing peptide receptor (“GRPR”)-targeting agent, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair, previously referred to as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 (and which we now refer to as LNTH-2402 and LNTH-2401, respectively), for an upfront payment of $35.0 million plus a $1.0 million payment made prior to the acquisition, and potential regulatory milestone payments plus royalties acquisition (the “RM2 Asset Purchase”). Purchase”), pursuant to the Sublicense, Development and Collaboration Agreement, by and between us and Life Molecular, dated as of June 27, 2024 (the “RM2 Sublicense Agreement”).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The primary working capital uses of cash were due to the timing of payments to large vendors, include an increase in trade receivables associated primarily with the increase timing of billings and collections and the acquisitions of Life Molecular and Evergreen in PYLARIFY revenues, and the year, an increase in inventory related to the timing of batch processes. processes and an increase in income tax receivable.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in financing activities during the year ended December 31, 2024 2025 is primarily attributable to the repurchase of our common stock for approximately $100.0 $300.0 million, the payments for minimum statutory tax withholding related to net share settlement of equity awards of $22.6 $26.3 million and the payment payments for finance leases of $2.3 million of financing costs related to the refinancing of our credit facility described below, $1.1 million, offset by proceeds of $6.7 $10.9 million from stock option exercises. exercises and issuance of common stock.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
In The 2025 Program replaced the program authorized by the Board in November 2024, our Board authorized a program 2024 to repurchase up to $250 million of our common stock during the next twelve months following the authorization (the “2024 Program”). Program”), including the remaining unused amounts under the 2024 Program.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We received an initial payment in 2023 of approximately $98.0 million in connection with the sale and have the right to receive an earned additional consideration of $5.0 million payment if worldwide net sales of RELISTOR in 2025 exceed as a specified threshold. result of the achievement of a sales-based milestone.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We generally sell our products outside the U.S. United States through a combination of direct distribution in Canada and third party Canada, third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America. America and by licensing exclusive rights to develop and commercialize certain products outside the United States.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our effective tax rate in fiscal 2024 2025 differs from the U.S. statutory rate of 21% primarily due to state income taxes and the valuation allowance established on the current year net unrealized loss on our investment in equity securities. taxes, partially offset by tax credits.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, 2025, we recorded an unrealized losses loss on the investments investment in Radiopharm of $3.6 million and recorded an unrealized loss on the investment in Perspective of $2.6 million and $41.0 million, respectively. $5.1 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new